ADVM — Adverum Biotechnologies Balance Sheet
0.000.00%
- $72.91m
- -$52.78m
- $1.00m
Annual balance sheet for Adverum Biotechnologies, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 430 | 305 | 186 | 96.5 | 126 |
Net Total Receivables | — | 5.71 | 0 | — | — |
Prepaid Expenses | |||||
Total Current Assets | 434 | 317 | 191 | 103 | 131 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 47.1 | 119 | 114 | 49.8 | 45.2 |
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 483 | 440 | 308 | 156 | 180 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 20.9 | 21.3 | 32.2 | 20 | 22.9 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 48.2 | 124 | 127 | 88.5 | 109 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 434 | 316 | 182 | 67.2 | 70.7 |
Total Liabilities & Shareholders' Equity | 483 | 440 | 308 | 156 | 180 |
Total Common Shares Outstanding |